Current Report Filing (8-k)
November 07 2019 - 4:16PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported): November 7, 2019
IMMUNIC, INC.
(Exact name of registrant as specified
in its charter)
|
Delaware
|
001-36201
|
56-2358443
|
(State or other jurisdiction
of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
1200 Avenue of the Americas, Suite 200
New York, NY 10036
USA
(Address of principal executive offices)
Registrant’s telephone number,
including area code: 49 89 250079460
Am Klopferspitz 19
82152 Martinsried
Germany
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading Symbol(s)
|
Name of exchange on which registered
|
|
Common Stock, par value $0.0001
|
IMUX
|
Nasdaq Capital Market
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§ 240.12b2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. Yes ☒
No ☐
Item 2.02. Results of Operations and Financial
Condition
On November 7, 2019, Immunic, Inc. issued
a press release announcing its financial results for the quarter ended September 30, 2019. The full text of the press release is
attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The information in this Item 2.02, and Exhibit
99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities
Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this current report
shall not be incorporated by reference into any registration statement or other document filed with the Securities and Exchange
Commission, whether filed before or after the date hereof regardless of any general incorporation language in any such filing,
unless the registrant expressly sets forth in such filing that such information is to be considered “filed” or incorporated
by reference therein.
Item 9.01. Financial Statements and Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
|
Dated: November 7, 2019
|
Immunic, Inc.
|
|
|
|
|
|
|
By:
|
/s/ Daniel Vitt
|
|
|
|
Daniel Vitt
|
|
|
|
Chief Executive Officer
|
Immunic (NASDAQ:IMUX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Immunic (NASDAQ:IMUX)
Historical Stock Chart
From Apr 2023 to Apr 2024
